111 related articles for article (PubMed ID: 17141529)
21. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.
Berg D; Merz B; Reiners K; Naumann M; Becker G
Mov Disord; 2005 Mar; 20(3):383-5. PubMed ID: 15486999
[TBL] [Abstract][Full Text] [Related]
22. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.
Berg D; Roggendorf W; Schröder U; Klein R; Tatschner T; Benz P; Tucha O; Preier M; Lange KW; Reiners K; Gerlach M; Becker G
Arch Neurol; 2002 Jun; 59(6):999-1005. PubMed ID: 12056937
[TBL] [Abstract][Full Text] [Related]
23. Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population.
Liepelt I; Wendt A; Schweitzer KJ; Wolf B; Godau J; Gaenslen A; Bruessel T; Berg D
J Neural Transm (Vienna); 2008 Jul; 115(7):993-9. PubMed ID: 18368284
[TBL] [Abstract][Full Text] [Related]
24. Does ultrasound disclose a vulnerability factor for Parkinson's disease?
Behnke S; Berg D; Becker G
J Neurol; 2003 Feb; 250 Suppl 1():I24-7. PubMed ID: 12761631
[TBL] [Abstract][Full Text] [Related]
25. Transcranial brain parenchyma sonography in movement disorders: state of the art.
Walter U; Behnke S; Eyding J; Niehaus L; Postert T; Seidel G; Berg D
Ultrasound Med Biol; 2007 Jan; 33(1):15-25. PubMed ID: 17189043
[TBL] [Abstract][Full Text] [Related]
26. Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV.
Obermann M; Küper M; Kastrup O; Yaldizli O; Esser S; Thiermann J; Koutsilieri E; Arendt G; Diener HC; Maschke M;
J Neurol; 2009 Jun; 256(6):948-53. PubMed ID: 19240951
[TBL] [Abstract][Full Text] [Related]
27. Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism.
Todd G; Pearson-Dennett V; Wilcox RA; Chau MT; Thoirs K; Thewlis D; Vogel AP; White JM
Parkinsonism Relat Disord; 2016 Apr; 25():27-32. PubMed ID: 26923520
[TBL] [Abstract][Full Text] [Related]
28. Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism.
Walter U; Rosales R; Rocco A; Westenberger A; Domingo A; Go CL; Brüggemann N; Klein C; Lee LV; Dressler D
Parkinsonism Relat Disord; 2017 Apr; 37():43-49. PubMed ID: 28094105
[TBL] [Abstract][Full Text] [Related]
29. Increased echogenicity of the substantia nigra in children and adolescents with attention-deficit/hyperactivity disorder.
Krauel K; Feldhaus HC; Simon A; Rehe C; Glaser M; Flechtner HH; Heinze HJ; Niehaus L
Biol Psychiatry; 2010 Aug; 68(4):352-8. PubMed ID: 20227683
[TBL] [Abstract][Full Text] [Related]
30. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy.
Berg D; Jabs B; Merschdorf U; Beckmann H; Becker G
Biol Psychiatry; 2001 Sep; 50(6):463-7. PubMed ID: 11566164
[TBL] [Abstract][Full Text] [Related]
31. Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra: a cross-sectional study.
Yu SY; Cao CJ; Zuo LJ; Chen ZJ; Lian TH; Wang F; Hu Y; Piao YS; Li LX; Guo P; Liu L; Yu QJ; Wang RD; Chan P; Chen SD; Wang XM; Zhang W
BMC Neurol; 2018 Jan; 18(1):9. PubMed ID: 29343241
[TBL] [Abstract][Full Text] [Related]
32. [Transcranial sonography findings in Parkinson's disease].
Izawa Okawa M; Miwa H
Brain Nerve; 2012 Apr; 64(4):413-22. PubMed ID: 22481514
[TBL] [Abstract][Full Text] [Related]
33. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits.
Beach TG; Sue LI; Walker DG; Lue LF; Connor DJ; Caviness JN; Sabbagh MN; Adler CH
Acta Neuropathol; 2007 Oct; 114(4):419-24. PubMed ID: 17639428
[TBL] [Abstract][Full Text] [Related]
34. Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease.
Huang YW; Jeng JS; Tsai CF; Chen LL; Wu RM
Mov Disord; 2007 Mar; 22(4):550-5. PubMed ID: 17260344
[TBL] [Abstract][Full Text] [Related]
35. Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease.
Pujol J; Junqué C; Vendrell P; Grau JM; Capdevila A
Arch Neurol; 1992 Nov; 49(11):1119-22. PubMed ID: 1444876
[TBL] [Abstract][Full Text] [Related]
36. Sonographic abnormality of the substantia nigra in melanoma patients.
Rumpf JJ; Weise D; Fricke C; Wetzig T; Simon JC; Classen J
Mov Disord; 2013 Feb; 28(2):219-23. PubMed ID: 23114984
[TBL] [Abstract][Full Text] [Related]
37. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.
Schweitzer KJ; Hilker R; Walter U; Burghaus L; Berg D
Mov Disord; 2006 Jan; 21(1):94-8. PubMed ID: 16114024
[TBL] [Abstract][Full Text] [Related]
38. Structural abnormality of substantia nigra induced by methamphetamine abuse.
Rumpf JJ; Albers J; Fricke C; Mueller W; Classen J
Mov Disord; 2017 Dec; 32(12):1784-1788. PubMed ID: 29082542
[TBL] [Abstract][Full Text] [Related]
39. Transcranial sonography in Huntington's disease.
Krogias C; Eyding J; Postert T
Int Rev Neurobiol; 2010; 90():237-57. PubMed ID: 20692506
[TBL] [Abstract][Full Text] [Related]
40. Transcranial sonography findings in welding-related Parkinsonism in comparison to Parkinson's disease.
Walter U; Dressler D; Lindemann C; Slachevsky A; Miranda M
Mov Disord; 2008 Jan; 23(1):141-5. PubMed ID: 17987651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
